Batea Oncology is a company headquartered in Spain.
Batea Oncology develops GlioHook, a class III medical device designed to improve treatment outcomes for glioblastoma by concentrating residual tumor cells after surgery and enhancing their sensitivity to radiotherapy.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.